Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Wichita, Kansas


Purpose:

The purpose of this study is to investigate a safe treatment interruption interval(s) for re-initiation of bifeprunox at a therapeutic dose. The study duration is approximately 7 to 10 weeks.


Criteria:

Inclusion Criteria: - Diagnosis of Schizophrenia or Schizoaffective disorder - 18-55 years Exclusion Criteria: - Subjects who are acutely psychotic - Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia - Subjects at significant risk of suicide - Subjects with a seizure disorder


NCT ID:

NCT00141479


Primary Contact:

Study Director
Global Clinical Director Solvay
Solvay Pharmaceuticals


Backup Contact:

N/A


Location Contact:

Wichita, Kansas
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 13, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.